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1. Introduction 
Gastrointestinal (GI) endoscopy has been widely used for detection, differentiation and 
staging for neoplasia in the digestive tract, and has made great progress during the last 
decade (Sivak, 2006). Diagnostic accuracy can be enhanced by better training, more efficient 
techniques, and the development of new image-processing technologies (Cotton et al., 2006; 
Tajiri, 2007); however, diagnosis using conventional endoscopy with optical characteristics 
is essentially limited because it is based on morphological changes and/or discoloration. 
Chromoendoscopy can enhance surface structure and to determine demarcation borders but 
is not enough for screening out of early cancer because it is still depending on endoscopists’ 
expertise and biopsy. Auto-fluorescence imaging system has been applied for lesions which 
have been difficult to morphologically recognize or are indistinct with conventional 
endoscope and this system has potential application for the diagnosis of dysplastic lesions 
and early cancers in the gastrointestinal tract. Optical digital enhancing method such as 
narrow band imaging (NBI), flexible spectral imaging color enhancement (FICE) and i-
SCAN are novel endoscopic techniques which can distinguish neoplastic and non-neoplastic 
lesions without the dye. Magnifying endoscopy in combination with optical digital method 
has an obvious advantage; the analysis of the epithelial pit pattern and the vascular 
network. Some of other techniques are allowing us to visualize cell morphology on the 
micro level reflection of microscopic characteristics. However, we should solve these 
problems; how to combine these technologies in diagnostic strategy, how to apply them into 
the algorithm for therapeutic decision and how to standardize several classifications of 
morphology surrounding them.  
‘Molecular imaging’ is a concept representing the most novel imaging methods in medicine, 
and the definition of the word is controversial. It is broadly defined as ‘the in vivo 
characterization and measurement of a biological process at the cellular molecular level’ 
(Weissleder & Mahmood, 2001) or as the technique that ‘directly or indirectly monitor and 
record the spatiotemporal distribution of molecular and cellular processes for biochemical, 
biological, diagnostic, or therapeutic application’ (Thakur & Lentle, 2005). Positron emission 
tomography (PET) might be included in a wide concept of molecular imaging methods: the 
detection, spatial localization, and quantification of specific molecular targets and events 
that form the basis of pathologies (Mahmood & Wallace, 2007). In the clinical setting of 
medical fields, a major paradigm shift has been rapidly taking place in imaging technology 
represented by PET. Similarly, in the field of GI endoscopy, the authors propose rapid 
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development of ‘endoscopic molecular imaging’, which is considered to be divided into 
three categories: (a) visualization of cell morphology on the micro to nano level; (b) 
reflection of spectroscopic characteristics; and (c) visualization of molecular characteristics. 
The future of endoscopic diagnosis is likely to be affected by a combination of biomarkers 
and technology (Takayama et al., 1998), and ‘endoscopic molecular imaging’ would be 
defined as (c), which has been described as ‘immunoscopy’ (Keller et al., 1998), 
‘bioendoscopy’ (Pasricha & Motamedi, 2002), and ‘optical biopsy’ (Fujimoto et al., 1995). 
These innovations will allow us not only to locate a tumor but also useful to 1) differentiate 
malignant and benign polyps and ulcers, 2) minimize number of biopsies and frequency of 
surveillance, 3) accurate preoperative identification of tumor margin, 4) evaluate 
effectiveness of pharmacological therapy, 5) detect local dysplasia in Barrett’s mucosa or 
ulcerative colitis. These will also allow us to visualize its molecular characteristics (e.g. DNA 
mutations and polymorphisms, gene and/or protein expression), and the activity of specific 
molecules and biological processes that affect tumor behavior and/or its response to 
therapy (Weissleder, 2006).  
Hsiung et al. detected in vivo human colonic dysplasia using a targeted heptapeptide 
topically administered and confocal microendoscopy in 2008 (Hsiung et al., 2008). Recently, 
Goetz et al. used confocal laser endomicroscopy (CRE) and fluorescently labeled epidermal 
growth factor receptor (EGFR) and succeeded in differentiating EGFR expression patterns in 
xenograft tumors and human neoplastic tissue samples (Goetz et al., 2010). These are 
promising future technologies that will play a central role in gastrointestinal oncology. We 
have been attempting to develop a novel imaging method using antibodies labeled with a 
fluorescent marker excitable by infrared rays and imaging modalities. In this section, we 
will describe our results and future directions of endoscopic molecular imaging in 
gastrointestinal oncology. 
2. Characteristics of infrared fluorescence 
Infrared radiation is light with wavelengths between 780 nm and 100 μm, and it has high 
permeability and safety compared to ultraviolet rays. These characteristics have been applied 
to various technologies such as non-destructive analysis of agricultural products, and infrared 
photography has been especially investigated in the medical field (Gibson et al., 1965; Mimura 
& Okuda, 1981). Infrared endoscopy has been used as a special diagnostic tool for examination 
of the gastrointestinal tract with or without intravenous injection of indocyanine green (ICG) 
(Kohso et al., 1990; Ohta et al., 1994; Iseki et al., 2000; Mataki et al., 2003; Ishihara, 2010) ; ICG is 
widely used as a reagent for clinical examination of hepatic function (Fox & Wood, 1960). ICG 
is a fluorescent agent that absorbs infrared rays and produces visible spots at the maximum 
wavelength of 805 nm (Nimura et al., 2004). ICG emits wavelengths of 807-832 nm on 
excitation at around 770 nm (Benson & Kues, 1978; Mordon et al., 1998; Muguruma et al., 
1999). Taking advantage of this characteristic, infrared fluorescence is used for retinal 
angiography (Flower, 1973) and the evaluation of burn depth (Still, 2001) and the patency of 
cardiac venografts (Detter et al., 2002). Recently, this property was applied to gastrointestinal 
blood vessels using a CCD camera (Borotto et al., 1999). In the living body, components or 
elements emit fluorescence of 310-540 nm when excited at 280-370 nm. In addition, there is 
little background noise in the living body (Shealy et al., 1995), especially in the digestive tract, 
which makes infrared fluorescence a likely candidate for development as a novel diagnostic 
system (Ganz, 2004; Okamoto et al., 2005). Several kinds of labeling agents for detecting 
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carcinomas in the digestive tract have been reported (Tatsuta, 1989; Pelegrin, 1991; Ballou et 
al., 1998), some of which fluoresce in visible or ultraviolet rays. However, application of UV is 
not suitable because it damages living tissue (Davies, 1995). ICG seems to be a suitable 
molecule for immunofluorescent diagnosis in the digestive tract such as esophagus, stomach, 
and colon because of its spectral properties and low toxicity.  
3. Fluorescent agents 
Although ICG binds albumin in a non-covalent way in the blood, it lacks a protein-binding 
group to bind antibodies. Therefore, we developed an ICG-N-hydroxysulfosuccinimide ester 
(ICG-sulfo-OSu) (Figure 1A) that has the ability to bind to proteins (Ito et al., 1995). The 
physiochemical characteristics resembled those of ICG: the absorption maximum was 795 nm, 
and it has a specific fluorescence emission at 807 nm upon excitation at 768 nm. However, the 
fluorescence intensity was not sufficient when it was labeled with an antibody. Consequently, 
Nagao et al. developed ICG-acylthiazolidinethione (ICG-ATT) (Figure 1B) (Hirata et al., 1998), 
which consists of the ICG skeleton, an alkyl side chain, and the thiazolidinethione amide 
group. The absorption maximum was 789 nm, and the fluorescent maximum was 830 nm 
upon excitation at 765 nm, reflecting the structure of the original ICG-dye moiety. Both 
materials proved to be near-infrared fluorescent agents (Figure 2), but it is unknown if ICG 
derivatives are toxic to living body in a clinical setting. Although precise toxicity tests have not 
been performed yet, ICG derivatives are expected to be non-toxic because the basic structures 
of these materials are similar to ICG, which is non-toxic.  
 
 
Fig. 1. The chemical structure of ICG-derivative; ICG-sulfo-OSu (A) and ICG-ATT (B). ICG-
sulfo-OSu has an ester group, a characteristic chemical structure capable of biding to various 
antibodies. ICG-ATT is also an infrared fluorescent-labeling reagent useful for proteins and 
amino acid compounds. 
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Fig. 2. Excitation spectrum (dotted line) and emission spectrum (continuous line) of ICG-
sulfo-OSu (A) and ICG-ATT (B). 
4. Labeled antibodies  
First, we labeled an anti-epithelial membrane antigen (EMA) antibody with ICG-sulfo-OSu. 
Although the anti-EMA antibody is not cancer-specific, this antibody is cross-reactive with 
normal epithelium in the digestive tract and has a relatively high sensitivity (Muguruma et 
al., 1998). Therefore, we first confirmed the sensitivity and specificity of 
immunofluorescence of the labeled antibody. Anti-EMA antibody (Dako, Denmark) was 
labeled with ICG-sulfo-OSu by our standardized method. Anti-EMA antibody (2.8 mg) was 
dissolved in 4 ml of 100 mM sodium bicarbonate buffer (pH 8.5), and 40 μl of 6 mM ICG-
sulfo-OSu dissolved in dimethylsulfoxide was added, followed by incubation at 37°C for 1 
hour. Based on our previous study, the molecular ratio of anti-EMA antibody to ICG-sulfo-
OSu was 1:12. The reaction mixture was purified with a Sephadex G-25M column (PD-10, 
Pharmacia, Sweden) using 50 mM phosphate-buffered saline (PBS) as an eluent. The dye-
conjugated antibody was separated from the free dye. The greenish solution of ICG-sulfo-
OSu labeled anti-EMA antibody was immediately freeze-dried. The physiochemical 
characters of the labeled antibody were similar to those of ICG. After confirmation of 
adequate immunofluorescence from this labeled antibody, we attempted to develop a 
cancer-specific labeled antibody. In fact, various cancer-specific antibodies, such as the anti-
CEA antibody, have been used as labeled antibodies for the diagnosis of gastrointestinal 
cancer (Keller et al., 2002). We have also labeled an anti-CEA antibody (Chemicon 
International Inc., CA, USA), which has a high sensitivity for gastrointestinal cancer (Page, 
1986), with ICG-sulfo-OSu. The excitation and emission spectra of ICG-sulfo-OSu labeled 
anti-CEA antibody was also similar to that of ICG (Muguruma et al., 1999). Although the 
labeled anti-CEA antibody showed efficient immunofluorescence, we developed a new 
labeled antibody using a more sensitive tumor marker. Mucin, a glycoprotein containing a 
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large amount of sugar, is the main component of mucus, and the peptide structure of the 
mucin core protein has been clarified (Kim, 1993). The specific expression of mucin in 
various cancers has been reported, and we also studied the staining pattern and evaluated 
its sensitivity in gastrointestinal cancers (Bando et al., 2002). Based on its relatively high 
sensitivity (Nakamori, 1994), we labeled an anti-MUC1 antibody (MY.1E12; kindly provided 
by Prof. Tatsuro Irimura, The University of Tokyo) with ICG-ATT.   
5. Imaging modality 
5.1 Infrared fluorescence microscope 
We developed an infrared fluorescence microscope for observation of tissue sections by 
modifying a conventional infrared microscope (BHSM-IR, Olympus, Japan). The excitation 
filter with a transmission wavelength of 710–790 nm was placed between the halogen lamp 
and the sample, and the barrier filter with a transmission wavelength of 810–920 nm was 
placed between the sample and the charge-coupled device (CCD) camera (Ito, 1997).  
 
 
Fig. 3. Reflected-type imaging system for detecting labeled substances excited by near-infrared 
rays. The light source was placed in the microscope, and samples were irradiated using a half 
mirror. The exciter filter was placed between the halogen lamp and the half mirror, and the 
barrier filter between the half mirror and the ICCD camera. Fluorescent signals were detected 
with the ICCD camera, captured with an image capturing device, and recorded in an image 
storage device. Based on the characteristics of the absorption and fluorescence spectra of ICG-
sulfo-Osu, band pass filters with transmission wavelengths of 710-790 nm and 810-920 nm 
were used as the exciter and barrier filter, respectively. 
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Fluorescent signals were detected by a CCD camera equipped with an image-capturing 
device and recorded in an image-storage device. All the images were processed by 
averaging original images, averaging background images, subtraction, noise filtering, and 
contrast enhancement. However, this transmission-type imaging system cannot be applied 
to an endoscopic system because the specimen is sandwiched between the excitation and 
barrier filters. We therefore developed a reflected-type infrared fluorescence microscopy: the 
light source was placed in the microscope, and the samples were irradiated using a half 
mirror (Figure 3) (Taoka, 1999). The excitation filter was placed between the halogen lamp 
and the half mirror and the barrier filter between the half mirror and the intensified charge 
coupled device (ICCD) camera. Light from the light source passes through the excitation 
filter, and about 50% of the light is reflected and irradiates the sample. About 50% of the 
fluorescence emitted from the sample passes through the barrier filter and is detected by the 
ICCD camera. Although the fluorescent input is reduced by 25% compared with that of 
previous type microscopy, theoretically the ICCD camera enhances the images better than 
the CCD camera equipped with the transmission type. Images were processed by a 
recursive filter, which can also average some images after emphasizing later images, on an 
ICCD controller to decrease noise. The efficiency of image processing using this recursive 
filter was expressed by the following equation: Vn · 1 + (Vin – Vn · 1) / N, where  
Vn = output image, Vn · 1 = the output image 1 frame earlier, Vin = input image, and  
N = constant (4, 16, 64). 
5.2 Infrared fluorescence endoscope  
Based on the results of immunofluorescence using infrared fluorescence microscopy, a 
prototype of infrared fluorescence endoscopy was developed to observe the human 
gastrointestinal tract (Figure 4) (Ito et al., 2001). The system consisted of an infrared 
endoscope (Olympus XGIF-Q40IR, Olympus) coupled with an image-capturing device. The 
light source, a 300 W xenon lamp, was also equipped with an excitation filter and a barrier 
filter, making it possible to observe fluorescence with the infrared excitation light and 
produce normal images under visible light. The ICCD camera was optically connected with 
the scope through an adapter into which the barrier filter was inserted. The new endoscopy 
system with a CCD at its tip has a greatly improved resolution: this system comprises of a 
light source apparatus, an infrared fluorescence endoscope, and image analysis software, 
which is the same as that used for a conventional system (Kimura et al., 2007).  The light 
source apparatus (XCLV-260HP-IRF, Olympus) has three built-in filters; an infrared ray cut 
filter, an infrared ray pass filter, and a RGB filter.  White light produced by a xenon arc lamp 
goes through the infrared ray cut filter or infrared ray pass filter and then through the RGB 
rotation filter.  The infrared ray cut filter is used for conventional observation and the 
infrared ray pass filter for infrared fluorescence observation.  The infrared ray pass filter can 
transmit rays of wavelengths between 540 nm and 560 nm in addition to infrared rays of 
wavelengths between 680 nm and 770 nm.  The reflected light of the former rays allow us to 
know where in the stomach we are looking during infrared fluorescence observation.  The 
RGB rotation filter can transmit light in the near-infrared region as well as the visible region. 
The infrared fluorescence endoscope (XGIFQ-240IRFZ, Olympus) is equipped with both a 
CCD with high resolution for conventional observation and a CCD with high sensitivity for 
infrared fluorescence observation at the top.  These two CCDs can be switched from one to 
another with a single touch of the button of the endoscope in conjunction with the switch 
from one filter to another (the infrared ray cut filter and infrared ray pass filter) in the light 
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source apparatus. Infrared rays excite the ICG-derivative-labeled antibody to emit 
fluorescence, which is subjected to barrier filters (825 to 945 nm) placed in front of the CCD 
for infrared fluorescence and is monitored as green signals on a pseudo-color display with 
an image processor (XCV-260HP-IRF, Olympus). 
 
 
Fig. 4. The schema of infrared fluorescence endoscope system. This system consisted of an 
infrared endoscope (Olympus XGIF-Q40IR, OLYMPUS) coupled with an image-capturing 
device. The light source that includes a 300 W xenon lamp which was equipped with an 
excitation filter and a barrier filter, so that it was possible to observe fluorescence with 
infrared excitation light and normal images under visible light. The ICCD camera was 
optically connected with the scope through an adapter into which the barrier filter was 
inserted. 
6. Ex vivo study of immunofluorescence with human stomach 
6.1 Immunofluorescence with microscope system 
Paraffin sections of human gastric mucosa, which had been previously proven to be positive 
in usual immunostaining for the anti-MUC1 antibody, were deparaffinized, and xylene was 
removed. After blocking endogenous peroxidase activity, sections were incubated with 
normal horse serum for 20 min, and then with the labeled antibodies at 500 mg/mL in 0.1M 
PBS for 10 min at room temperature. Observationwas performed under the infrared 
fluorescence imaging device to compare the fluorescence intensity of each preparation. 
Adjacent sections processed in the same way were incubated with the primary antibody, 
and then treated with the secondary antibody and the ABC reagent (avidin biotinylated 
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peroxidase complex) for 30 min. Preparations were visualized by 3-3‘ diaminobenzidine 
(DAB), and counter-stained by hematoxylin and methyl green. Localization of infrared 
fluorescence and DAB coloring was compared in serial sections. Subsequently, 
immunofluorescence of the paraffin sections of human gastric mucosa with ICG ATT-
labeled anti-MUC1 antibody produced stronger fluorescence than that by ICG-sulfo-OSu-
labeled antibody (Figure 5). Localization pattern of infrared fluorescent staining was in good 
agreement with that by the conventional method with oxidized DAB staining, which 
confirmed that the fluorescence due to the ICG ATT-labeled was more specific and sensitive 
to MUC1. 
 
 
Fig. 5. Images of infrared fluorescent microscopy for gastric cancer specimen reacted with 
ICG-derivative labeled anti-MUC1 antibody. A) ICG-sulfo-OSu labeled anti-MUC1 
antibody, B) ICG-ATT labeled anti-MUC1 antibody. The fluorescence intensity of the 
antigen stained with ICG-ATT labeled antibody was markedly stronger than that treated 
with ICG-sulfo-OSu labeled antibody. 
6.2 Immunofluorescence with endoscope system 
The immunoreactions of CEA with ICG-sulfo-OSu labeled anti-CEA antibody were 
examined in freshly resected human gastric cancer specimens using the infrared 
fluorescence endoscope.  The resected stomach tissue was treated with warm water of 37℃ 
containing 20000 U of Pronase, 1 g of NaHCO3, and 4 mg of dimethylpolysiloxane for 15 
min at room temperature to remove mucus adhering to the mucosa. The sample was treated 
with normal horse serum (blocking serum) for 15 min. The surface of the lesion and normal 
mucosa were then treated with ICG-derivative-labeled antibody for 60 min at room 
temperature (Ito et al., 2001). Then, normal mucosa and the cancerous area were compared 
using the infrared fluorescence endoscope. Infrared fluorescence was observed in the 
cancerous lesion, but not in the non-cancerous areas (Figure 6). Paraffin sections of the 
stomach encompassing the infrared fluorescence-positive site were stained with anti-CEA 
antibody using the ABC method. The immunoreactive staining was positive only in the 
cancerous lesions but was negative in the non-cancerous lesions. In the infrared 
fluorescence-positive sites, the carcinoma tissue was exposed on the mucosal surface.  
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Fig. 6. Infrared fluorescence imaging of freshly resected human gastric cancer tissue using 
ICG-sulfo-OSu-labeled anti-human carcinoembryonic antigen (CEA) antibody and an 
infrared fluorescence endoscope. The cancerous areas were stained with the fluorescent anti-
CEA antibody complex. A) The image observed under visible rays. B) The image observed 
under infrared rays (Ito-S, et al. Endoscopy 33: 849-853, 2001). Reprinted with permission 
 
 
Fig. 7. Infrared fluorescence image of freshly resected human gastric cancer tissue using ICG-
ATT-labeled MUC1 antibody A) The image of a cancerous lesion observed under white light. 
B) The image observed under infrared fluorescence after reaction of ICG-ATT labeled anti-
MUC1 antibody. Strong fluorescence was detected corresponding to the lesion. C) The image 
of a non-cancerous lesion under white light. D) There was no obvious fluorescence under 
infrared fluorescence observation (Ito-S, et al. Biomedical Thermology 23:77–97, 2003). 
Reprinted with permission 
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Subsequently, The same protocol was applied for other series of fresh specimen with gastric 
cancer using with ICG-ATT labeled anti-MUC1 antibody. In the cancerous lesions, the 
immunofluorescence of MUC1 labeled with ICG-ATT was strongly recognized, while there 
was no obvious fluorescence in the normal mucosa (Figure 7A and 7B). Paraffin sections of 
the specimen were stained with MUC1 antibody, and the fluorescence-positive sites and the 
immunoreaction with non-labeled MUC1 antibody corresponded well. 
7. Reinforcement of fluorescence intensity 
Some types of drugs (octylglucosid, OG) are known to be useful as reinforcement agents (Ito 
et al., 1998). The peak fluorescence wavelength lengthened with increasing concentration; an 
increase in the OG concentration from 10 to 100 mM resulted in a shift of the peak 
fluorescence wavelength from 800 to 817 nm. In a study with paraffin sections of human 
gastric cancer, slight fluorescence was observed without OG; however, with 100 mM OG, 
marked fluorescence was observed (Inayama et al., 2003). In another study, we assessed the 
relationship between the fluorescence and protein ratio (F/P ratio) and fluorescence 
intensity (Tadatsu, 2006). During purification of the labeled antibody, the concentration of 
each labeling compound reacting with 1 molecule of the antibody was varied as follows: 4, 
8, 16, and 32 molar equivalents. Subsequently, the intensity of fluorescence was evaluated 
by spectroscopy and infrared fluorescence microscopy. When the fluorescent antibody 
labeled with ICG-ATT was used at an F/P ratio of 2.94 or 4.18, clear and specific fluorescent 
images of the antigen were obtained. When the ICG-ATT-labeled antibody was used at an 
F/P ratio of 6.50 or 6.75, the fluorescence intensity decreased and the fluorescent images of 
the antigen became unclear. Therefore, the lower binding molar ratios of ICG-ATT were 
more useful for labeling the antibody. In previous studies, the whole IgG molecule was 
commonly used for preparation of labeled antibodies. However, labeled IgG displays 
insufficient sensitivity and specificity, probably resulting from nonspecific binding of the Fc 
fragment to target cells or molecular structure-dependent interference between 
fluorochromes. We characterized an Fc-free fluorescence-labeled Fab fragment, which was 
expected to yield more-specific binding to target cells than the whole IgG molecule. An anti-
mucin antibody and ICG-ATT were used as the labeled antibody and labeling compound, 
respectively. Paraffin sections of excised gastric cancer tissues were subjected to staining. 
The labeled whole IgG molecule (ICG-ATT-labeled IgG) and the labeled Fab fragment (ICG-
ATT-labeled Fab) were prepared according to a previous report, and the features of 
fluorescence microscopy images obtained from paraffin sections were compared. The 
fluorescence intensity obtained from paraffin sections of excised gastric cancer tissues 
tended to be greater with ICG-ATT-labeled Fab than with ICG-ATT-labeled IgG. 
Fragmentation of antibodies is considered to contribute to improved sensitivity and 
specificity of labeled antibodies for detection of micro gastrointestinal cancers (Yano, 2006). 
(Figure 8) 
8. In vivo reaction for exogenous antibody  
In vivo immunostaining is essential for utilization of this technique in endoscopic diagnosis; 
however, no method has been established yet (Hayashi, 1999). We examined in vivo 
immunostaining using nude mice.  A human gastric cancer was transplanted into the mice, 
and the tumor was exposed under ether anesthesia. A tissue sample was collected after 
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treatment with an antibody, and immunostaining was performed using the ABC method.  
Where anti-MUC1 mucin antibody had been applied in vivo to the cleaved surface of the 
grafted gastric cancer, the reaction product was demonstrated by the luminosity of the 
neoplastic tissue. In positive controls, strong reactivity was seen, but in the negative control, 
reactivity was not observed (Kusaka et al., 2000). 
 
Fig. 8. The area stained with the unlabeled MUC1 antibody is shown in A.  
Immunofluorescence images of sections treated with ICG-ATT-labeled IgG (B) and ICG-
ATT-labeled Fab (C) are also shown. Stronger fluorescence was detected and the localization 
pattern of infrared fluorescence of the ICG-ATT-labeled Fab antibody was in better 
agreement with that of DAB in conventional immunohistochemistry compared with the 
ICG-ATT-labeled IgG antibody (Yano-H, et al. Photodiagnosis and Photodynamic Therapy 
3: 177-183, 2006). Reprinted with permission 
9. Conclusions 
Molecular imaging was listed as one of the "ten emerging technologies that will change the 
world" by the Massachusetts Institute of Technology (MIT) 2003 Technology Review. 
Recently, in the USA, the National Institutes of Health has launched common fund 
programs in which ‘Molecular Libraries and Imaging’ is included (National Institute of 
Health, 2011). In EU, Diagnostic Molecular Imaging (DiMI) and European Master in 
Molecular Imaging (EMMI) have been organized. DiMI Network of Excellence was one of 
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the largest European research projects funded by the European Commission within the 6th 
Framework Programme (Diagnostic Molecular Imaging, n.d.). EMMI is an international 
program entirely dedicated to in vivo molecular imaging. Supported by the European 
Commission under the SOCRATES programme, this two-year interdisciplinary curriculum 
is brought together by prominent European molecular imaging research groups (European 
Master in Molecular Imaging, n.d.). Given this situation, it is convincing that molecular 
imaging is one of the latest upcoming and nationwide fields that affect human life science. 
Molecular imaging can add various types of information to conventional imaging 
techniques and enable not only detection and localization but also quantification and the 
basis of pathologies (Mahmood and Wallace, 2007). In terms of one specific paradigm of the 
technology, the exogenous administration of targeted probes may provide additional and 
complementary information to native spectro-endomicroscopic image analysis of lesions. It 
also can be used to either image the administered drug directly to access its distribution and 
target binding. 
In general, the incidence of colorectal cancer in the world has been increasing and will occur 
more frequently in the coming generations; a new technology is therefore required that it is 
cost-effective and efficient for both screening and further examinations. It is well known that 
there are many alterations in the molecular pathways of carcinoma; stepwise formation will 
be visualized with various molecules. The fluorescence signal acquired by endoscopy is not 
quantitative by itself, but the intensity of the signal is expected to reveal the depth or 
potential of a cancer. Moreover, amplification or reinforcement strategies are required 
because focal target concentrations are quite low, in the pico- to nanomolar range 
(Weissleder, 1999). Ideal system in this technology should offer a strong signal-to noise 
ratio, quantitative analysis, less invasive modality, real time monitoring and multiplex 
imaging using various fluorescent peptides or antibodies with different optical 
characteristics. Before the application of diagnostic drug to clinical use, pharmacokinetics 
and pharmacodynamics should be tested and these agents have to undergo lengthy 
approval processes; however, no definite barriers are anticipated to prevent its clinical 
application because therapeutic administration of various humanized antibodies has proven 
safe and imaging and therapeutic targets are often same. On the other hand, fluorochromes 
such as ICG are photostable and have been used safely in the human body. With these 
possibilities, it seems apparent that this innovative technology will be realized in 
cooperation with the pharmaceutical industry, chemical company and engineering 
manufacture, hopefully with their investment in the economic market of gastrointestinal 
oncology. 
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As result of progress, endoscopy has became more complex, using more sophisticated devices and has
claimed a special form. In this moment, the gastroenterologist performing endoscopy has to be an expert in
macroscopic view of the lesions in the gut, with good skills for using standard endoscopes, with good
experience in ultrasound (for performing endoscopic ultrasound), with pathology experience for confocal
examination. It is compulsory to get experience and to have patience and attention for the follow-up of
thousands of images transmitted during capsule endoscopy or to have knowledge in physics necessary for
autofluorescence imaging endoscopy. Therefore, the idea of an endoscopist has changed. Examinations
mentioned need a special formation, a superior level of instruction, accessible to those who have already
gained enough experience in basic diagnostic endoscopy. This is the reason for what these new issues of
endoscopy are presented in this book of New techniques in Gastrointestinal Endoscopy.
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